{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T09:46:37Z","timestamp":1766137597946},"reference-count":35,"publisher":"Medical Association of Nippon Medical School","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nippon Med Sch"],"published-print":{"date-parts":[[2021,10,25]]},"DOI":"10.1272\/jnms.jnms.2021_88-518","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T22:09:23Z","timestamp":1610748563000},"page":"423-431","source":"Crossref","is-referenced-by-count":2,"title":["Effect of Topiroxostat on Brain Natriuretic Peptide Level in Patients with Heart Failure with Preserved Ejection Fraction: A Pilot Study"],"prefix":"10.1272","volume":"88","author":[{"given":"Masaki","family":"Wakita","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuniya","family":"Asai","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Kubota","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Koen","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Hamaguchi S, Furumoto T, Tsuchihashi-Makaya M, et al. Hyperuricemia predicts adverse outcomes in patients with heart failure. Int J Cardiol. 2011 Sep 1;151(2):143-7.","DOI":"10.1016\/j.ijcard.2010.05.002"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Okazaki H, Shirakabe A, Kobayashi N, et al. The prognostic impact of uric acid in patients with severely decompensated acute heart failure. J Cardiol. 2016 Nov;68(5):384-91.","DOI":"10.1016\/j.jjcc.2016.04.013"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Palazzuoli A, Ruocco G, Pellegrini M, et al. Prognostic significance of hyperuricemia in patients with acute heart failure. Am J Cardiol. 2016 May 15;117(10):1616-21.","DOI":"10.1016\/j.amjcard.2016.02.039"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Huang WM, Hsu PF, Cheng HM, et al. Determinants and prognostic impact of hyperuricemia in hospitalization for acute heart failure. Circ J. 2016;80(2):404-10.","DOI":"10.1253\/circj.CJ-15-0964"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Bergamini C, Cicoira M, Rossi A, Vassanelli C. Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure. Eur J Heart Fail. 2009 May;11(5):444-52.","DOI":"10.1093\/eurjhf\/hfp042"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Spiekermann S, Landmesser U, Dikalov S, et al. Electron spin resonance characterization of vascular xanthine and NAD (P) H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation. 2003 Mar 18;107(10):1383-9.","DOI":"10.1161\/01.CIR.0000056762.69302.46"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol. 2011 Dec;301(6):H2181-90.","DOI":"10.1152\/ajpheart.00554.2011"},{"key":"8","unstructured":"8. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013 Jul 23;62(4):263-71."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Shimizu T, Yoshihisa A, Kanno Y, et al. Relationship of hyperuricemia with mortality in heart failure patients with preserved ejection fraction. Am J Physiol Heart Circ Physiol. 2015 Oct;309(7):H1123-9.","DOI":"10.1152\/ajpheart.00533.2015"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Redfield MM. Heart failure with preserved ejection fraction. N Engl J Med. 2016 Nov 10;375(19):1868-77.","DOI":"10.1056\/NEJMcp1511175"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, et al. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J. 2009 Oct;73(10):1893-900.","DOI":"10.1253\/circj.CJ-09-0254"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ. 2005 Mar 19;330(7492):625.","DOI":"10.1136\/bmj.330.7492.625"},{"key":"13","unstructured":"13. Kuki S, Matsuyama A, Masuno T, Hayashi Y. Kounyosankessho wo gappeishita shinkekkanshikkan hairisuku kanja niokeru topirokisosutatto no siyoukeiken [The clinical experience of topiroxostat in patients at high risk cardiovascular disease]. Ther Res. 2016;37(1):49-57. Japanese."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Nakamura T, Murase T, Satoh E, et al. The influence of albumin on the plasma xanthine oxidoreductase inhibitory activity of allopurinol, febuxostat and topiroxostat: Insight into extra-urate lowering effect. Integr Mol Med [Internet]. 2019;6(3). Available from: https:\/\/doi.org\/10.15761\/IMM.1000368","DOI":"10.15761\/IMM.1000368"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Nakamura T, Murase T, Nampei M, et al. Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db\/db mice. Eur J Pharmacol. 2016 Jun 5;780:224-31.","DOI":"10.1016\/j.ejphar.2016.03.055"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail. 2016 Aug;18(8):891-975.","DOI":"10.1002\/ejhf.592"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012 Oct;64(10):1447-61.","DOI":"10.1002\/acr.21773"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Suzuki S, Yoshimura M, Nakayama M, et al. Plasma level of B-type natriuretic peptide as a prognostic marker after acute myocardial infarction: a long-term follow-up analysis. Circulation. 2004 Sep 14;110(11):1387-91.","DOI":"10.1161\/01.CIR.0000141295.60857.30"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Murase T, Oka M, Nampei M, Miyachi A, Nakamura T. A highly sensitive assay for xanthine oxidoreductase activity using a combination of [ (13) C2, (15) N2 ]xanthine and liquid chromatography\/triple quadrupole mass spectrometry. J Labelled Comp Radiopharm. 2016 May 15;59(5):214-20.","DOI":"10.1002\/jlcr.3390"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Murase T, Nampei M, Oka M, Miyachi A, Nakamura T. A highly sensitive assay of human plasma xanthine oxidoreductase activity using stable isotope-labeled xanthine and LC\/TQMS. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Dec 15;1039:51-8.","DOI":"10.1016\/j.jchromb.2016.10.033"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Murase T, Nampei M, Oka M, et al. Xanthine oxidoreductase activity assay in tissues using stable isotope-labeled substrate and liquid chromatography high-resolution mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Jan 1;1008:189-97.","DOI":"10.1016\/j.jchromb.2015.11.030"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Tanaka A, Shimabukuro M, Okada Y, et al. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial. Cardiovasc Diabetol. 2017 Apr 12;16(1):48.","DOI":"10.1186\/s12933-017-0532-8"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Gavin AD, Struthers AD. Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart. 2005 Jun;91(6):749-53.","DOI":"10.1136\/hrt.2004.040477"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation. 2002 Jul 9;106(2):221-6.","DOI":"10.1161\/01.CIR.0000022140.61460.1D"},{"key":"25","unstructured":"25. Xiao J, Deng SB, She Q, et al. Allopurinol ameliorates cardiac function in non-hyperuricaemic patients with chronic heart failure. Eur Rev Med Pharmacol Sci. 2016 Feb;20(4):756-61."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. El Assar M, Angulo J, Rodriguez-Manas L. Oxidative stress and vascular inflammation in aging. Free Radic Biol Med. 2013 Dec;65:380-401.","DOI":"10.1016\/j.freeradbiomed.2013.07.003"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Hare JM, Mangal B, Brown J, et al. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol. 2008 Jun 17;51(24):2301-9.","DOI":"10.1016\/j.jacc.2008.01.068"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Givertz MM, Anstrom KJ, Redfield MM, et al. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. Circulation. 2015 May 19;131(20):1763-71.","DOI":"10.1161\/CIRCULATIONAHA.114.014536"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Otaki Y, Watanabe T, Kinoshita D, et al. Association of plasma xanthine oxidoreductase activity with severity and clinical outcome in patients with chronic heart failure. Int J Cardiol. 2017 Feb 1;228:151-7.","DOI":"10.1016\/j.ijcard.2016.11.077"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018 Mar 29;378(13):1200-10.","DOI":"10.1056\/NEJMoa1710895"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Zhang M, Solomon DH, Desai RJ, et al. Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol. Circulation. 2018 Sep 11;138(11):1116-26.","DOI":"10.1161\/CIRCULATIONAHA.118.033992"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Matsumoto K, Okamoto K, Ashizawa N, Nishino T. FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductase. J Pharmacol Exp Ther. 2011 Jan;336(1):95-103.","DOI":"10.1124\/jpet.110.174540"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Kojima S, Matsui K, Hiramitsu S, et al. Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy. Eur Heart J. 2019 Jun 7;40(22):1778-86.","DOI":"10.1093\/eurheartj\/ehz119"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Mizukoshi T, Kato S, Ando M, et al. Renoprotective effects of topiroxostat for Hyperuricaemic patients with overt diabetic nephropathy study (ETUDE study): A prospective, randomized, multicentre clinical trial. Nephrology. 2018;23(11):1023-30.","DOI":"10.1111\/nep.13177"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Imai E, Horio M, Yamagata K, et al. Slower decline of glomerular filtration rate in the Japanese general population: a longitudinal 10-year follow-up study. Hypertens Res. 2008 Mar;31(3):433-41.","DOI":"10.1291\/hypres.31.433"}],"container-title":["Journal of Nippon Medical School"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/88\/5\/88_JNMS.2021_88-518\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T03:56:39Z","timestamp":1637380599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/88\/5\/88_JNMS.2021_88-518\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,25]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1272\/jnms.jnms.2021_88-518","relation":{},"ISSN":["1345-4676","1347-3409"],"issn-type":[{"value":"1345-4676","type":"print"},{"value":"1347-3409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,25]]},"article-number":"JNMS.2021_88-518"}}